Immunotherapy for Prostate Cancer: An Emerging Treatment Modality

Charles G. Drake

doi:10.1016/j.ucl.2009.11.001

Immunotherapy for Prostate Cancer: An Emerging Treatment Modality

Charles G. Drake

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies.

Original language	English (US)
Pages (from-to)	121-129
Number of pages	9
Journal	Urologic Clinics of North America
Volume	37
Issue number	1
DOIs	https://doi.org/10.1016/j.ucl.2009.11.001
State	Published - Feb 2010

Keywords

CTLA4
Lymphocyte
PD-1
Prostate cancer
T cell
Vaccine

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.ucl.2009.11.001

Fingerprint Dive into the research topics of 'Immunotherapy for Prostate Cancer: An Emerging Treatment Modality'. Together they form a unique fingerprint.

Cite this

@article{52ff1fed1792458f9f354a646ed48609,

title = "Immunotherapy for Prostate Cancer: An Emerging Treatment Modality",

abstract = "This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies.",

keywords = "CTLA4, Lymphocyte, PD-1, Prostate cancer, T cell, Vaccine",

author = "Drake, {Charles G.}",

year = "2010",

month = feb,

doi = "10.1016/j.ucl.2009.11.001",

language = "English (US)",

volume = "37",

pages = "121--129",

journal = "Urologic Clinics of North America",

issn = "0094-0143",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Immunotherapy for Prostate Cancer

T2 - An Emerging Treatment Modality

AU - Drake, Charles G.

PY - 2010/2

Y1 - 2010/2

N2 - This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies.

AB - This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies.

KW - CTLA4

KW - Lymphocyte

KW - PD-1

KW - Prostate cancer

KW - T cell

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=75349096325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75349096325&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2009.11.001

DO - 10.1016/j.ucl.2009.11.001

M3 - Article

C2 - 20152525

AN - SCOPUS:75349096325

VL - 37

SP - 121

EP - 129

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 1

ER -